Frank Schestag, PhD, Joins Proteintech as Commercial Director in Europe
Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing leadership to the sales and marketing teams and growing the markets in Germany, Austria, and Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005684/en/
Dr. Frank Schestag, Proteintech Commercial Director (Photo: Business Wire)
Dr. Schestag comes to Proteintech with 18 years of experience in sales and management of scientific reagents and equipment. At Fisher Scientific as Director of Sales and then promoted to Senior Sales Director of the Life Science Solution Group (Life Technologies), he led teams over 50 sales specialists in central Europe and responsible for over $200M in revenue. Throughout his career, Dr. Schestag has exceled in building teams, whether it be technical support, sales, logistics, or accounting. Besides high performance, his sites have consistently scored the highest in employee satisfaction and engagement.
“Europe has always been at the forefront of science. Frank’s experience in leadership will enable us to better serve Europe’s scientific community as well as the pharmaceutical and biomedical communities,” says Proteintech CEO Jason Li.
“I am very excited to become a member of the Proteintech Group. For me, it is a perfect fit to support Proteintech with the experience I have gained in the last 20 years in science, sales, operations, and the European market,” says new Proteintech Commercial Director, Dr. Frank Schestag, “I believe it will bring us more successes than we’re already seeing today.”
Dr. Schestag received his PhD in Biochemistry at the Christian-Albrechts-University in Kiel. Afterward, he began his career at Fermentas, a manufacturer of molecular biology products. He was responsible for developing the business in technical support, customer service, and commercial organization. As the Sales Director for Europe, he built up and led a direct sales team operating in 15 different European countries. In large part due to Dr. Schestag’s stewardship, Fermentas accelerated in growth and was acquired by Thermo Fisher, where he transitioned to General Manager and Site Leader. Through these experiences, Dr. Schestag has gained an intimate knowledge of the German market and how to drive growth there.
About Proteintech Group
Proteintech is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering nearly all research areas. With its acquisition of Humanzyme, Proteintech now offers the Humankine® product line of animal-free human-cell expressed proteins. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, CHIP, and KD/KO siRNA experiments using our antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com
Proteintech Group, Inc.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Topcon to Attend EURETINA 2019 Meeting21.8.2019 07:00:00 EEST | Press release
Topcon Europe Medical, a leading provider of medical devices and software solutions for the European eye care community, is excited to announce its participation in EURETINA 2019, the European Society of Retinal Specialists’ annual congress, which has become internationally renowned as the largest retina meeting worldwide. On 5-8 September, thousands of vitreoretinal and macula specialists will gather at the Palais des Congrès de Paris in France to share information on the latest trends and advances in vitreoretinal surgery and the diagnosis and treatment of retinal diseases including macular degeneration and diabetic retinopathy. Topcon will be located in the Exhibit Hall, Level 2 at Booth #219 and will showcase its latest innovative technology solutions for today’s retina specialists including the Triton Swept Source OCT, the newly released Maestro Fully Automated OCT with Angiography, Artificial Intelligence systems, the all new Topcon Signal Hand-held Camera, and the PASCAL Laser S
IFF to Present at Barclays Global Consumer Staples Conference September 520.8.2019 23:15:00 EEST | Press release
Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients today announced that the Company’s management will speak at the Barclays Global Consumer Staples Conference in Boston, Massachusetts, on Thursday, Sept 5, 2019 at 2:15 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/ho
Novalis LifeSciences Launches its First Life Science Investment Fund with $85 Million20.8.2019 19:29:00 EEST | Press release
August 20th, 2019, Novalis LifeSciences, an investment and advisory firm for the Life Science industry, announced today that it has raised $85M in capital for its first fund - Novalis LifeSciences Investments I, L.P. Novalis LifeSciences is focused on highly innovative Life Science companies. On the occasion of closing the first fund, Marijn E. Dekkers, founder and chairman, said: “This first fund is a growth-oriented fund that will invest in 8-12 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. This includes drug discovery, life science tools, genomics, synthetic biology, diagnostics, and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors”. About Novalis LifeSciences Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former ch
Bermuda Tech Week 2019 to Celebrate Innovation and Explore Opportunities for Growth20.8.2019 17:27:00 EEST | Press release
Registration is under way and filling fast for Bermuda Tech Week 2019 which will take place at the Hamilton Princess & Beach Club from October 14-18, 2019. The programme of insightful and engaging events will explore future opportunities and challenges presented by emerging technologies such as artificial intelligence, blockchain, digital assets, insurtech and virtual reality. It will showcase Bermuda’s ongoing success in creating a welcoming, stable and well-regulated environment where technology and start-up companies can thrive. “Bermuda has a long history of innovation so we understand and recognise the power of technology to positively impact both the economy and society,” said Bermuda Premier David Burt. “Over the past two years, we have built on our strength as a global leader in regulating the risks associated with the global insurance industry to develop a clear regulatory framework around managing the risks associated with Fintech. Our progressive approach has drawn accolades
Limelight Networks Expands Developer Toolkit With New API and Portal Enhancements20.8.2019 17:25:00 EEST | Press release
Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of edge cloud services, today announced it has expanded the management and configuration capabilities of its suite of services with new Application Programming Interfaces (APIs) and web portal offerings. With these new capabilities in addition to existing APIs and Software Development Kits, developers now have more power to manage and monitor services across Limelight’s edge cloud platform. According to an IDC surveyi, more than half the organizations surveyed have already adopted DevOps practices, with an additional 20 percent planning to do so in the next 12 months. To help organizations meet these demands, Limelight has introduced expanded API capabilities to provide developers with access to the full set of configuration options available across its content delivery services. Limelight’s new Configuration API enables developers to configure Limelight services and programmatically integrate them into their workflows. It exp
Andersen Global Enters Zimbabwe20.8.2019 16:30:00 EEST | Press release
Andersen Global announced it has signed a collaboration agreement with Chimwamurombe Legal Practice (Zenas) in Zimbabwe. Andersen Global has built a presence in over 14 African countries in just under two years. Zenas was founded in 2015 and now has a team of 11 professionals who provide legal services to individuals, organizations, institutions and corporations. With a specialty of serving small to medium enterprises, they offer solutions in mining and construction, commercial, debt recovery, property law, labor law, family law, tax, technology, telecommunications, media and intellectual property law, and criminal litigation. “When we started, we set out to be the most sought-after, trusted legal firm in Zimbabwe,” said Fungai Chimwamurombe, Zenas Office Managing Director. “These values line up very closely with those firms in the Andersen Global international organization. We are happy to join a team of professionals that is equally committed to treating clients like family and deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom